Progenics Pharma Cash Flow - Annual (NASDAQ:PGNX)

Add to My Stocks
$6.42 $0.42 (7%) PGNX stock closing price Sep 19, 2018 (Closing)

For analyzing any company like Progenics Pharma from an investment perspective, its important to check the cash flow statement. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Progenics Pharma profits one has to check the income statement and for Progenics Pharma debt one has to check the balance sheet. The cash flow statement is essetial while conducting the Progenics Pharma cash flow analysis and can be used to measure the operating performance of Progenics Pharma compared to various industry peers like VYGR stock and ADMS stock. The cash from operating activities for Progenics Pharma is $ 2017, which saw a decrease from previous year.

View details of Progenics Pharma cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow1.12M2.07M-3.22M1.85M1.32M2.06M2.85M5.96M5.56M
Net Increase (Decrease) in Assets Liabilities-6.22M-5.99M2.25M1.41M-6.74M-0.42M10.94M-38.24M-3.33M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net-4.44M-4.41M3.84M3.18M6.2M6.36M9.51M13.08M14.13M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.23M-3.93M-0.32M-0.57M--0.37M-0.22M-2.17M-0.9M-2.17M
Acquisition Disposition of Subsidiaires---6.2M-1.88M-----
Increase (Decrease) in Investments---2.4M1.1M--1.7M80.23M72.49M
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares5.49M1.34M1.73M37.88M40.14M23.65M3.72M3.89M4.87M3.71M
Issuance (Repayment) of Debt Securities-48.65M--------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities--0.36M-0.29M--0.04M-----
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash--0.08M--------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year138.9M74.1M119.3M65.86M58.83M70.1M47.91M90.9M56.18M10.42M
Cash & Equivalents at Year End90.64M138.9M74.1M119.3M65.86M58.83M70.1M47.91M90.9M56.18M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Progenics Pharma stock comparison chart provides an easy way to compare the stock price with peers along with details of Progenics Pharma stock price history.
The statement of cash flows can be categorized into three main sections:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Progenics Pharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Progenics Pharma stock price movement.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-53.62M for PGNX.
  • Cash Flow from investment activities: Progenics Pharma used $-0.23M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $5.51M for Progenics Pharma.

Key Financial Ratios For Progenics Pharma Cash Flow